Merck & Co., Inc. (MRK) to Release Quarterly Earnings on Tuesday

Merck & Co., Inc. (NYSE:MRK) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Merck & Co., Inc. to announce earnings of ($0.26) per share and revenue of $16.3492 billion for the quarter. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:00 AM ET.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the prior year, the business earned $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. On average, analysts expect Merck & Co., Inc. to post $3 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $134.09 on Tuesday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm’s 50-day moving average price is $122.03 and its two-hundred day moving average price is $117.94. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $133.82. The stock has a market capitalization of $331.17 billion, a P/E ratio of 37.74, a P/E/G ratio of 5.20 and a beta of 0.19.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds have recently made changes to their positions in the business. State Street Corp boosted its position in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after buying an additional 1,859,990 shares during the period. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after buying an additional 11,156,354 shares in the last quarter. Morgan Stanley increased its position in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock valued at $4,731,018,000 after acquiring an additional 359,486 shares during the period. Bank of America Corp DE increased its position in Merck & Co., Inc. by 6.1% in the 4th quarter. Bank of America Corp DE now owns 27,854,441 shares of the company’s stock valued at $2,931,958,000 after acquiring an additional 1,602,005 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MRK shares. Morgan Stanley increased their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Wells Fargo & Company raised their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.